Aarti Drugs: Low Demand, High RM Prices Impact Profitability; Capex to Drive Growth
We expect revenue and PAT CAGR of 13.3% and 12.3% respectively over the period FY21-FY23E and recommend BUY with TP of Rs 760.
332 Views
𝛼SK or SearchENTITY
Aarti Drugs (ARTD IN)
Aarti Drugs (ARTD IN)
28
Analysis
Health Care • India
Aarti Drugs is a prominent Indian pharmaceutical company specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and specialty chemicals. It produces over 50 API molecules and 80+ finished products for various therapeutic segments, including anti-protozoals, anti-inflammatory, antibiotics, and antidiabetics, serving both domestic and international markets. The company was founded in 1984 and is headquartered in Mumbai, Maharashtra, India.
morex